Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;14(4):345.
Epub 2025 Jul 3.

Efficacy of Interventions for Newly Diagnosed Multiple Myeloma: An Umbrella Review

Yimeng Li  1 , Mengmeng Ji  2 , Mark A Fiala  3 , Enkhjin Gansukh  1 , Natalia Neparidze  4   5 , Martin W Schoen  6   7 , Xiaomei Ma  1   5 , Graham A Colditz  2 , Su-Hsin Chang  2 , Shi-Yi Wang  1   5
Affiliations

Efficacy of Interventions for Newly Diagnosed Multiple Myeloma: An Umbrella Review

Yimeng Li et al. J Clin Exp Oncol. 2025 Aug.

Abstract

Purpose: Many systematic reviews have examined treatment efficacy for newly diagnosed multiple myeloma (NDMM). We performed an umbrella review of these systematic reviews to provide a comprehensive examination of the current body of evidence, aiming to scope current review-level evidence and identify weaknesses in these reviews.

Methods: We identified systematic reviews examining efficacy of NDMM interventions in multiple databases published from January 1, 1990 through July 10, 2023. We explored potentially concerning issues which may compromise the validity of the conclusions in these reviews. We assessed the reviews' quality, summarized the findings, and present potential evidence gaps.

Results: Eighty-seven reviews on NDMM treatment were included. Only seven assessed the strength of evidence. Treatments strategies like bortezomib-based induction for transplant-eligible patients, daratumumab for transplant-ineligible patients, and lenalidomide maintenance had moderate to high evidence. No reviews evaluated chimeric antigen receptor T-cell therapy or bispecific antibodies for NDMM. We identified five concerning issues: 1) inappropriate data abstraction (N=6), 2) inappropriate meta-analytic approaches (N=5), 3) not accounting for different induction strategies when evaluating the efficacy of consolidation/maintenance therapies (N=9), 4) implicit assumption that treatment efficacy is similar between transplant eligible and ineligible patients (N=13), and 5) inappropriate study selection (including observational studies or single-arm trials for treatment efficacy evaluation, which may lead to substantial biases; N=17).

Conclusion: This umbrella review provided a contemporary analysis of treatment efficacy for NDMM. We identified several weaknesses in existing reviews, indicating additional scrutiny of publishing systematic reviews in MM is warranted.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest Dr Schoen reported receiving personal fees from Pfizer and ConcertAI outside the submitted work. Dr Ma served as a consultant for Bristol Myers Squibb. Dr Colditz reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Wang reported receiving grants from the American Cancer Society outside the submitted work. Dr Neparidze received research funding (institutional) from Janssen and GSK. None of these interests were related to the development of this manuscript. The remaining authors declare no competing financial interests.

Figures

Figure 1:
Figure 1:
Flowchart for study selection and review.
See this image and copyright information in PMC

References

    1. Kumar SK, Rajkumar V, Kyle RA, Van Duin M, Sonneveld P, et al. (2017) Multiple myeloma. Nat Rev Dis Primer; 3:17046. - PubMed
    1. Palumbo A, Anderson K. (2011) Multiple myeloma. N Engl J Med; 364(11):1046–1060. - PubMed
    1. Higgins J, Altman D, Sterne JA. (2011) Assessing risk of bias in included studies (Chapter 8). Cochrane Handb Syst Rev Interv Version; 5(0).
    1. Kumar A, Galeb S, Djulbegovic B. (2011) Treatment of patients with multiple myeloma: An overview of systematic reviews. Acta Haematol; 125(1–2):8–22. - PubMed
    1. Aguiar PM, de Mendonça Lima T, Colleoni GWB, Storpirtis S. (2017) Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses. Crit Rev Oncol Hematol; 113:195–212. - PubMed

LinkOut - more resources